Evidence map›Paper›PMID 25202838›Full record

ReviewCurrent opinion in nephrology and hypertension2014

Molecular monitoring of alloimmune-mediated injury in kidney transplant patients.

Opas Traitanon, Emilio D Poggio, Robert L Fairchild

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in nephrology and hypertension, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Expanding role of antibodies in kidney transplantation.World journal of transplantation · 2025
    Review
  2. Advances in Detection of Kidney Transplant Injury.Molecular diagnosis & therapy · 2019
    Review
  3. Elevated serum vascular endothelial growth factor and development of cardiac allograft vasculopathy in children.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2018
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Opas TraitanonaDivision of Nephrology, Department of Internal Medicine, Thammasart University, Pathumthani, Thailand bDepartment of Immunology, Lerner Research Institute cDepartment of Nephrology, Glickman Urological Institute, Cleveland Clinic dDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Emilio D Poggio
Robert L Fairchild
Cleveland Clinic Lerner College of Medicine · USThammasat University · THUniversity School · US

Funding

Noninvasive Markers and Transplant Outcome in HumansU01AI063594 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HEEGER, PETER SCOTT · 2004 to 2022
$66.5M
POSTTRANSPLANT INFLAMMATORY RESPONSER01AI040459 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI Robert L Fairchild · 1997 to 2026
$9.4M
Alloreactive T Cell Immunity in Human Transplant CandidatesK23AI068824 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI POGGIO, EMILIO DANIEL · 2007 to 2011
$540k
NIAID NIH HHS AI63594-06NIAID NIH HHS K23 AI068824NIAID NIH HHS K23-AI68824NIAID NIH HHS P01 AI087506NIAID NIH HHS R01 AI040459NIAID NIH HHS R01-AI40459NIAID NIH HHS U01 AI063594
6 · The paper itself

Abstract

purpose of reviewRapid progress in molecular technology has allowed development of numerous molecular tools to help the clinician to evaluate graft status in kidney transplant patients. This review highlights recent findings, describing the use of molecular approaches to monitor, diagnose, and predict alloimmune-mediated injury in kidney grafts. RECENT

findingsBoth previously identified and newly discovered molecular markers of immune injury have been studied and validated in large multicenter studies. Recent data indicate that measuring specific gene transcripts in noninvasive samples, such as urine or peripheral blood, can identify the occurrence of acute rejection and differentiate this immune-mediated injury from other causes of graft dysfunction. Serial monitoring of urine in stable renal transplant patients may detect the onset of rejection before development of graft dysfunction. Moreover, combining gene expression analysis with conventional histopathologic assessment of grafts can enhance the accuracy of diagnosis and may also help predict graft outcomes. SUMMARY: Measuring specific gene transcription in noninvasive clinical samples has the potential to become an important and standard tool to monitor alloimmune-mediated injury in kidney transplant recipients. Prospective studies are ongoing to validate these findings for use of these approaches in clinical settings.

Indexed as

Molecular Diagnostic TechniquesAcute DiseaseGenetic MarkersGraft RejectionHumansIsoantibodiesKidney TransplantationMicroRNAsMonitoring, ImmunologicPredictive Value of TestsRNA, MessengerTreatment OutcomeGenetic MarkersIsoantibodiesMicroRNAsRNA, Messenger

Identifiers

PMID25202838
PMCPMC7577053
OpenAlexW2318653303

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.